This content is machine translated Immunosuppression in prostate cancer New therapeutic targets are being explored What is certain: The survival prognosis of metastatic castration-resistant prostate cancer (mCRPC) has improved – on average from just over one (before 2000) to almost three years [1]. Nevertheless, current…